194 related articles for article (PubMed ID: 18682975)
1. Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker.
Kouch-el Filali M; Kilic E; Melis M; de Klein A; de Jong M; Luyten GP
Graefes Arch Clin Exp Ophthalmol; 2008 Nov; 246(11):1585-92. PubMed ID: 18682975
[TBL] [Abstract][Full Text] [Related]
2. Expression of nm23-H1 in uveal melanoma.
Bakalian S; Marshall JC; Faingold D; Logan P; Antecka E; Burnier MN
Melanoma Res; 2007 Oct; 17(5):284-90. PubMed ID: 17885583
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.
Harda K; Szabo Z; Szabo E; Olah G; Fodor K; Szasz C; Mehes G; Schally AV; Halmos G
Molecules; 2018 Jun; 23(7):. PubMed ID: 29949880
[TBL] [Abstract][Full Text] [Related]
4. Expression of somatostatin receptors in uveal melanomas.
Ardjomand N; Ardjomand N; Schaffler G; Radner H; El-Shabrawi Y
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):980-7. PubMed ID: 12601018
[TBL] [Abstract][Full Text] [Related]
5. Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma.
Jiang Z; Liu F
Med Sci Monit; 2019 Apr; 25():3190-3198. PubMed ID: 31039142
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma.
Dror R; Lederman M; Umezawa K; Barak V; Pe'er J; Chowers I
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):1811-6. PubMed ID: 19892878
[TBL] [Abstract][Full Text] [Related]
7. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity.
Taylor JE; Theveniau MA; Bashirzadeh R; Reisine T; Eden PA
Peptides; 1994; 15(7):1229-36. PubMed ID: 7854974
[TBL] [Abstract][Full Text] [Related]
8. Expression of the metastasis suppressor gene KISS1 in uveal melanoma.
Martins CM; Fernandes BF; Antecka E; Di Cesare S; Mansure JJ; Marshall JC; Burnier MN
Eye (Lond); 2008 May; 22(5):707-11. PubMed ID: 18219339
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
[TBL] [Abstract][Full Text] [Related]
10. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
11. EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation.
Neumann LC; Weinhäusel A; Thomas S; Horsthemke B; Lohmann DR; Zeschnigk M
BMC Cancer; 2011 Aug; 11():380. PubMed ID: 21871071
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
Dalm VA; Hofland LJ; Mooy CM; Waaijers MA; van Koetsveld PM; Langerak AW; Staal FT; van der Lely AJ; Lamberts SW; van Hagen MP
J Nucl Med; 2004 Jan; 45(1):8-16. PubMed ID: 14734660
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors.
Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S
Int J Clin Oncol; 2019 Dec; 24(12):1526-1535. PubMed ID: 31377937
[TBL] [Abstract][Full Text] [Related]
14. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines.
Refaian N; Schlereth SL; Koch KR; Notara M; Hos D; Mescher M; Iden S; Bosch JJ; Jager MJ; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5691-7. PubMed ID: 26313304
[TBL] [Abstract][Full Text] [Related]
16. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.
Maloney SC; Marshall JC; Antecka E; Orellana ME; Fernandes BF; Martins C; Castiglione E; DI Cesare S; Logan P; Burnier MN
Anticancer Res; 2009 Aug; 29(8):3059-64. PubMed ID: 19661316
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma.
Lederman M; Meir T; Zeschnigk M; Pe'er J; Chowers I
Curr Eye Res; 2008 Oct; 33(10):876-84. PubMed ID: 18853322
[TBL] [Abstract][Full Text] [Related]
18. High EIF4E2 expression is an independent prognostic risk factor for poor overall survival and recurrence-free survival in uveal melanoma.
Yang B; Gu A; Wu Y
Exp Eye Res; 2021 May; 206():108558. PubMed ID: 33785306
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma.
Benhassine M; Le-Bel G; Guérin SL
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163491
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic Plasticity in Uveal Melanoma Is Not Restricted to a Tumor Subpopulation and Is Unrelated to Cancer Stem Cell Characteristics.
Doherty RE; Sisley K; Hammond DW; Rennie IG; Cross NA
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5387-5395. PubMed ID: 29049740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
